JP2024544499A - 遺伝子工学的改変により得られた、分泌能と凝固活性を向上させた組換えヒト第viii因子 - Google Patents

遺伝子工学的改変により得られた、分泌能と凝固活性を向上させた組換えヒト第viii因子 Download PDF

Info

Publication number
JP2024544499A
JP2024544499A JP2024526888A JP2024526888A JP2024544499A JP 2024544499 A JP2024544499 A JP 2024544499A JP 2024526888 A JP2024526888 A JP 2024526888A JP 2024526888 A JP2024526888 A JP 2024526888A JP 2024544499 A JP2024544499 A JP 2024544499A
Authority
JP
Japan
Prior art keywords
fviii
hfviii
factor viii
human factor
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544499A5 (cg-RX-API-DMAC7.html
Inventor
董▲びあお▼
張波
叶静▲や▼
肖�琳
鄭趙悦
楊茘
劉瑜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Real&best Biotech Co Ltd
Original Assignee
Sichuan Real&best Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Real&best Biotech Co Ltd filed Critical Sichuan Real&best Biotech Co Ltd
Publication of JP2024544499A publication Critical patent/JP2024544499A/ja
Publication of JP2024544499A5 publication Critical patent/JP2024544499A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024526888A 2021-11-25 2022-02-11 遺伝子工学的改変により得られた、分泌能と凝固活性を向上させた組換えヒト第viii因子 Pending JP2024544499A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021133004 2021-11-25
CNPCT/CN2021/133004 2021-11-25
PCT/CN2022/075976 WO2023092864A1 (en) 2021-11-25 2022-02-11 Engineered human fviii with enhanced secretion ability and clotting activity

Publications (2)

Publication Number Publication Date
JP2024544499A true JP2024544499A (ja) 2024-12-03
JP2024544499A5 JP2024544499A5 (cg-RX-API-DMAC7.html) 2025-02-10

Family

ID=84487686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526888A Pending JP2024544499A (ja) 2021-11-25 2022-02-11 遺伝子工学的改変により得られた、分泌能と凝固活性を向上させた組換えヒト第viii因子

Country Status (5)

Country Link
US (1) US20240254197A1 (cg-RX-API-DMAC7.html)
EP (1) EP4211153A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024544499A (cg-RX-API-DMAC7.html)
CN (3) CN118638211A (cg-RX-API-DMAC7.html)
WO (1) WO2023092864A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209942A1 (en) * 2013-06-24 2014-12-31 Weidong Xiao Mutant factor viii compositions and methods
WO2016123200A1 (en) * 2015-01-30 2016-08-04 Emory University Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
JP2020519272A (ja) * 2017-05-09 2020-07-02 エモリー ユニバーシティー 凝固因子変異体及びその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
EP1985631A1 (en) * 2007-04-20 2008-10-29 LFB Biotechnologies Demannosylated recombinant factor VIII for the treatment of patients with hemophiila A
WO2013123457A1 (en) * 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US20160311885A1 (en) * 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
CN108884145B (zh) * 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
KR102219859B1 (ko) * 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
TWI851647B (zh) * 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2022165390A1 (en) * 2021-01-29 2022-08-04 Expression Therapeutics, Llc Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209942A1 (en) * 2013-06-24 2014-12-31 Weidong Xiao Mutant factor viii compositions and methods
WO2016123200A1 (en) * 2015-01-30 2016-08-04 Emory University Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
JP2020519272A (ja) * 2017-05-09 2020-07-02 エモリー ユニバーシティー 凝固因子変異体及びその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Accession No. XP_023615755", NCBI [ONLINE], JPN6025053010, 2018, ISSN: 0005767417 *
"Accession No. XP_036160738", NCBI [ONLINE], JPN6025053011, 2020, ISSN: 0005767418 *
BRITISH JOURNAL OF HAEMATOLOGY, vol. 131, JPN6026016987, 2005, pages 109 - 117, ISSN: 0005856731 *
東医大誌, vol. 64, no. 4, JPN6026016986, 2006, pages 380 - 387, ISSN: 0005856730 *

Also Published As

Publication number Publication date
CN118546234A (zh) 2024-08-27
CN116710554B (zh) 2024-06-07
TW202321290A (zh) 2023-06-01
WO2023092864A1 (en) 2023-06-01
CN118638211A (zh) 2024-09-13
US20240254197A1 (en) 2024-08-01
EP4211153A4 (en) 2023-11-01
CN116710554A (zh) 2023-09-05
EP4211153A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
US20240207392A1 (en) Epstein-barr virus mrna vaccines
US20240226277A1 (en) Influenza-coronavirus combination vaccines
CN112225793B (zh) 一种溶酶体靶向肽及其融合蛋白、携带融合蛋白编码序列的腺相关病毒载体及其应用
TW202310880A (zh) 靶向肌肉之基因療法之功效改進
CN111718947B (zh) 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途
EP4069849B1 (en) Liver-specific promoter and application thereof
CN114929872A (zh) 用nadh脱氢酶蛋白治疗莱伯遗传性视神经病变的组合物和方法
TW202221126A (zh) 用於鑑別及特徵化指環病毒之方法及其用途
WO2024230802A1 (en) Engineered liver-specific core promoters and their applications
WO2026017126A1 (zh) 一种人工设计的新型nrg-1在疾病治疗中的应用
CN116710554B (zh) 基因工程改造获得的分泌能力和凝血活性增强的人类八因子
RU2852567C2 (ru) Сконструированный полипептид человеческого фактора VIII (hFVIII) с повышенной коагулирующей активностью, фрагмент выделенной нуклеиновой кислоты, вектор экспрессии (варианты), фармацевтическая композиция для лечения гемофилии A и способ ее лечения
US20240277834A1 (en) Nucleic acid molecules
BR112019017444A2 (pt) regulação da expressão gênica por acessibilidade mediada por aptâmero de sinais de poliadenilação
US20250121096A1 (en) Engineered liver-specific enhancers and their applications
TWI893802B (zh) 工程化的肝臟特異性增強子、核心啟動子及其應用
HK40120431A (en) Engineered liver-specific core promoters and their applications
CN115838725B (zh) 在哺乳动物心脏中特异性启动基因的启动子序列及其应用
CN119685289A (zh) 一种用于调控CaMKII-δ亚型选择性表达的单碱基编辑系统
CN121472228A (zh) 3’ utr元件、重组载体及其制备方法和应用
CN112695032A (zh) 一种启动子pLRRK2及其应用
CN120242072A (zh) 一种治疗代谢性疾病的mRNA、药物组合物及应用
CN117683143A (zh) 一种编码血管内皮生长因子A融合蛋白的mRNA分子及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260512